ABBVIE INC (4AB.DE) Stock Fundamental Analysis

FRA:4AB • US00287Y1091

191.2 EUR
+0.6 (+0.31%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 4AB. 4AB was compared to 78 industry peers in the Biotechnology industry. 4AB has an average financial health and profitability rating. 4AB is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year 4AB was profitable.
  • 4AB had a positive operating cash flow in the past year.
  • Of the past 5 years 4AB 4 years were profitable.
  • Of the past 5 years 4AB 4 years had a positive operating cash flow.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • 4AB has a Return On Assets of 1.75%. This is in the better half of the industry: 4AB outperforms 76.92% of its industry peers.
  • 4AB has a Return On Invested Capital of 15.64%. This is amongst the best in the industry. 4AB outperforms 92.31% of its industry peers.
  • 4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is above the industry average of 11.39%.
  • The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • The Profit Margin of 4AB (3.94%) is better than 79.49% of its industry peers.
  • 4AB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 33.05%, 4AB belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
  • 4AB's Operating Margin has declined in the last couple of years.
  • 4AB has a better Gross Margin (71.16%) than 61.54% of its industry peers.
  • In the last couple of years the Gross Margin of 4AB has declined.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
  • There is no outstanding debt for 4AB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • 4AB has an Altman-Z score of 2.42. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.42, 4AB is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
  • 4AB has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as 4AB would need 3.49 years to pay back of all of its debts.
  • 4AB has a better Debt to FCF ratio (3.49) than 82.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.42
ROIC/WACC1.88
WACC8.3%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
  • 4AB has a Current ratio of 0.72. This is in the lower half of the industry: 4AB underperforms 76.92% of its industry peers.
  • A Quick Ratio of 0.60 indicates that 4AB may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.60, 4AB is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • 4AB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.19%.
  • 4AB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.99% yearly.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%

3.2 Future

  • Based on estimates for the next years, 4AB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.77% on average per year.
  • The Revenue is expected to grow by 6.33% on average over the next years.
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • 4AB is valuated rather expensively with a Price/Earnings ratio of 22.47.
  • Compared to the rest of the industry, the Price/Earnings ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 84.62% of the companies listed in the same industry.
  • 4AB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
  • 4AB is valuated correctly with a Price/Forward Earnings ratio of 15.47.
  • 4AB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 94.87% of the companies in the same industry.
  • 4AB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.47
Fwd PE 15.47
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 4AB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 4AB is cheaper than 82.05% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 89.74% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.18
EV/EBITDA 16.27
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of 4AB may justify a higher PE ratio.
  • A more expensive valuation may be justified as 4AB's earnings are expected to grow with 21.41% in the coming years.
PEG (NY)0.5
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y21.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • 4AB has a Yearly Dividend Yield of 3.04%. Purely for dividend investing, there may be better candidates out there.
  • 4AB's Dividend Yield is rather good when compared to the industry average which is at 0.47. 4AB pays more dividend than 97.44% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, 4AB pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.04%

5.2 History

  • The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
  • 4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ABBVIE INC

FRA:4AB (2/20/2026, 7:00:00 PM)

191.2

+0.6 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap337.92B
Revenue(TTM)N/A
Net Income(TTM)2.35B
Analysts77.3
Price Target213.99 (11.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.04%
Yearly Dividend5.26
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)0.49%
PT rev (3m)2.15%
EPS NQ rev (1m)-18.13%
EPS NQ rev (3m)-21.02%
EPS NY rev (1m)-6.64%
EPS NY rev (3m)-5.77%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE 22.47
Fwd PE 15.47
P/S 6.66
P/FCF 20.18
P/OCF 19.04
P/B N/A
P/tB N/A
EV/EBITDA 16.27
EPS(TTM)8.51
EY4.45%
EPS(NY)12.36
Fwd EY6.46%
FCF(TTM)9.48
FCFY4.96%
OCF(TTM)10.04
OCFY5.25%
SpS28.71
BVpS-1.27
TBVpS-44.57
PEG (NY)0.5
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.42
F-Score7
WACC8.3%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year-0.19%
EBIT Next 3Y15.91%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (4AB.DE). This can be considered as Undervalued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 4 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.